Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis.

IF 2.1 4区医学 Q3 GENETICS & HEREDITY

BMC Medical Genomics Pub Date : 2025-02-17 DOI:10.1186/s12920-025-02103-w

Fangjun Chen, Xing Gu, Guangliang Qiang

{"title":"Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis.","authors":"Fangjun Chen, Xing Gu, Guangliang Qiang","doi":"10.1186/s12920-025-02103-w","DOIUrl":null,"url":null,"abstract":"Background: In recent years, several studies have shown that HSPG2 is associated with the prognosis of specific cancers. The aim of this study was to investigate the prognostic value of HSPG2 in pan-cancer and to analyze its possible mechanisms.Methods: We used The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) to explore the expression of HSPG2 in 33 tumors and corresponding controls. Univariate Cox regression and Kaplan-Meier survival analysis were applied to detect the effects of HSPG2 on overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in patients with these tumors, and to analyze the relationship between HSPG2 and clinical characteristics. And we further analyzed the relationship between HSPG2 and immune infiltration, DNA methylation and single cell function. And GO and KEGG enrichment analyses were performed using HSPG2 co-expressed genes. Finally, we explored the diagnostic efficacy of HSPG2 for diseases of interest and validated it using qPCR experiment.Results: HSPG2 was lowly expressed in 17 cancers and highly expressed in 11 cancers, and was correlated with patient's clinical characteristics in many cancers. Multivariate regression analysis showed that HSPG2 was an independent prognostic factor for DSS, OS, and PFI in bladder urothelial carcinoma (BLCA) and Mesothelioma (MESO). HSPG2 was correlated with DNA methylation, single-cell function, and immune infiltration in a variety of cancers. HSPG2 exhibited a good diagnostic efficacy for BLCA and MESO. qPCR and western blot results showed that HSPG2 expression was increased in mesothelioma compared to normal controls.Conclusion: These findings suggest that HSPG2 could be considered as a potential diagnostic and prognostic marker for BLCA and MESO.","PeriodicalId":8915,"journal":{"name":"BMC Medical Genomics","volume":"18 1","pages":"33"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831783/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medical Genomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12920-025-02103-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In recent years, several studies have shown that HSPG2 is associated with the prognosis of specific cancers. The aim of this study was to investigate the prognostic value of HSPG2 in pan-cancer and to analyze its possible mechanisms.

Methods: We used The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) to explore the expression of HSPG2 in 33 tumors and corresponding controls. Univariate Cox regression and Kaplan-Meier survival analysis were applied to detect the effects of HSPG2 on overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in patients with these tumors, and to analyze the relationship between HSPG2 and clinical characteristics. And we further analyzed the relationship between HSPG2 and immune infiltration, DNA methylation and single cell function. And GO and KEGG enrichment analyses were performed using HSPG2 co-expressed genes. Finally, we explored the diagnostic efficacy of HSPG2 for diseases of interest and validated it using qPCR experiment.

Results: HSPG2 was lowly expressed in 17 cancers and highly expressed in 11 cancers, and was correlated with patient's clinical characteristics in many cancers. Multivariate regression analysis showed that HSPG2 was an independent prognostic factor for DSS, OS, and PFI in bladder urothelial carcinoma (BLCA) and Mesothelioma (MESO). HSPG2 was correlated with DNA methylation, single-cell function, and immune infiltration in a variety of cancers. HSPG2 exhibited a good diagnostic efficacy for BLCA and MESO. qPCR and western blot results showed that HSPG2 expression was increased in mesothelioma compared to normal controls.

Conclusion: These findings suggest that HSPG2 could be considered as a potential diagnostic and prognostic marker for BLCA and MESO.

查看原文本刊更多论文

HSPG2作为预后指标的综合泛癌分析。

背景：近年来，多项研究表明HSPG2与特定癌症的预后相关。本研究旨在探讨HSPG2在泛癌中的预后价值，并分析其可能的机制。方法：采用肿瘤基因组图谱（TCGA）和基因型组织表达（GTEx）对33例肿瘤及相应对照中HSPG2的表达进行分析。采用单因素Cox回归和Kaplan-Meier生存分析检测HSPG2对这些肿瘤患者总生存期（OS）、疾病特异性生存期（DSS）和无进展间期（PFI）的影响，并分析HSPG2与临床特征的关系。进一步分析了HSPG2与免疫浸润、DNA甲基化和单细胞功能的关系。使用HSPG2共表达基因进行GO和KEGG富集分析。最后，我们探索了HSPG2对感兴趣疾病的诊断效果，并通过qPCR实验验证了其诊断效果。结果：HSPG2在17种肿瘤中低表达，在11种肿瘤中高表达，在许多肿瘤中与患者临床特征相关。多因素回归分析显示，HSPG2是膀胱尿路上皮癌（BLCA）和间皮瘤（MESO）患者DSS、OS和PFI的独立预后因素。在多种癌症中，HSPG2与DNA甲基化、单细胞功能和免疫浸润相关。HSPG2对BLCA和MESO有较好的诊断效果。qPCR和western blot结果显示，与正常对照相比，间皮瘤组织中HSPG2的表达增加。结论：HSPG2可作为BLCA和MESO的潜在诊断和预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Medical Genomics 医学-遗传学

CiteScore

3.90

自引率

0.00%

发文量

243

审稿时长

3.5 months

期刊介绍： BMC Medical Genomics is an open access journal publishing original peer-reviewed research articles in all aspects of functional genomics, genome structure, genome-scale population genetics, epigenomics, proteomics, systems analysis, and pharmacogenomics in relation to human health and disease.